1	Title: Machine Learning Reveals Synovial Fibroblast Genes Associated
2	with Pain Affect Sensory Nerve Growth in Rheumatoid Arthritis
3	One Sentence Summary: Machine Learning reveals synovial fibroblast genes related to pain
4	affect sensory nerve growth in Rheumatoid Arthritis addresses unmet clinical need.
5	
6	Authors: Zilong Bai ¹ , Nicholas Bartelo ¹ , Maryam Aslam ² , Caryn Hale ² , Nathalie E. Blachere ² ,
7	Salina Parveen ² , Edoardo Spolaore ³ , Edward DiCarlo ³ , Ellen Gravallese ⁴ , Melanie H. Smith ³ ,
8	Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus
9	Erythematosus (AMP RA/SLE) Network, Mayu O. Frank ² , Caroline S. Jiang ² , Haotan Zhang ¹ ,
10	Myles J. Lewis ⁵ , Shafaq Sikandar ⁵ , Costantino Pitzalis ^{5,6} , Anne-Marie Malfait ⁷ , Rachel E.
11	Miller ⁷ , Fan Zhang ⁸ , Susan Goodman ³ , Robert Darnell ² , Fei Wang ¹ *, Dana E. Orange ^{2,3} *
12	Affiliations:
13	¹ Weill Cornell Medical College, New York
14	² Rockefeller University, New York, NY
15	³ Hospital for Special Surgery, New York, NY
16	⁴ Brigham and Women's Hospital, Boston, MA
17	⁵ Queen Mary University of London, United Kingdom
18	⁶ Department of Biomedical Sciences, Humanitas University & IRCC Humanitas Research
19	Hospital, Milan, Italy
20	⁷ Rush University Medical Center, Chicago, IL
21	⁸ University of Colorado, Anschutz, CO
22	

- 23 *Corresponding Authors
- 24 Fei Wang
- 25 Department of Population Health Sciences
- 26 Weill Cornell Medicine
- 27 425 East 61th Street
- 28 New York, NY, 10065
- 29 646-962-9405
- 30 few2001@med.cornell.edu
- 31
- 32 Dana E. Orange
- 33 Rockefeller University
- 34 1230 York Avenue
- 35 New York, NY, 10065
- 36 917-439-9625
- 37 dorange@rockefeller.edu

38

Abstract: It has been presumed that rheumatoid arthritis (RA) joint pain is related to
inflammation in the synovium; however, recent studies reveal that pain scores in patients do not
correlate with synovial inflammation. We identified a module of 815 genes associated with pain,
using a novel machine learning approach, Graph-based Gene expression Module Identification
(GbGMI), in samples from patients with longstanding RA, but limited synovial inflammation at
arthroplasty, and validated this finding in an independent cohort of synovial biopsy samples from
early, untreated RA patients. Single-cell RNA-seq analyses indicated these genes were most

robustly expressed by lining layer fibroblasts and receptor-ligand interaction analysis predicted robust lining layer fibroblast crosstalk with pain sensitive CGRP+ dorsal root ganglion sensory neurons. Netrin-4, which is abundantly expressed by lining fibroblasts and associated with pain, significantly increased the branching of pain-sensitive CGRP+ neurons *in vitro*. We conclude GbGMI is a useful method for identifying a module of genes that associate with a clinical feature of interest. Using this approach, we find that Netrin-4 is produced by synovial fibroblasts in the absence of inflammation and can enhance the outgrowth of CGRP+ pain sensitive nerve fibers.

53 Main Text:

54 INTRODUCTION

The four classic signs of inflammation are rubor, tumor, calor, and dolor – or redness, swelling, warmth, and pain. Inflammatory pain can be driven by cytokines, bradykinins, and prostanoids, which bind specific receptors on primary sensory neurons to cause heightened sensation of pain (*1*). Clinically, pain is not always proportional to inflammation and clinical scenarios in which pain is dissociated from inflammation are useful to study the non-inflammatory drivers of pain.

60

61 Rheumatoid arthritis (RA) is a chronic disease characterized by inflammation in the synovium, the tissue that lines the joint cavity. Despite great progress in developing an array of conventional 62 synthetic, targeted synthetic, and biologic disease-modifying anti-rheumatic drugs (csDMARDs, 63 64 ctDMARDs, and bDMARDs), which target relevant immune mediators (2), up to 20% of patients with RA are "difficult-to-treat", that is they do not improve despite treatment with at least two 65 bDMARD or tsDMARDs, with different mechanisms of action, after failing a csDMARD (3) It 66 67 has been assumed that synovial inflammation is the cause of RA joint pain, however, recent studies have revealed that pain can be dissociated from inflammation in RA (4-8). Patients with RA and 68

69 limited synovial inflammation, also known as "fibroid", "low inflammatory" or "pauci-immune" 70 synovium have as much pain as those with extreme inflammation (9-11). Patients with low 71 inflammatory synovium tend to receive less benefit from treatment with anti-inflammatory drugs 72 such as TNF inhibitors and disease-modifying anti-rheumatic drugs (DMARDs) (12,13), making 73 their management particularly challenging for clinicians, and suggesting that traditional 74 inflammatory pathways may not be the source of their discomfort.

75

Here, we performed a focused analysis on low inflammatory synovium to identify factors, beyond 76 inflammation, that relate to and might mediate joint pain. Due to the small number of patients 77 limiting the statistical power and patient reported outcome data being notoriously noisy, no 78 existing machine learning approach is adequately powered to identify pain-associated gene 79 modules from RA patients with low synovial inflammation. We developed a novel Machine 80 Learning approach, called Graph-based Gene expression Module Identification (GbGMI). Using 81 82 GbGMI, we discovered a group of 815 genes associated with pain in samples from patients with established RA but low synovial inflammation. We validated the pain-associated gene module on 83 internal data and a second dataset of patients with early RA. Using sorted-cell subsets and single-84 85 cell RNA-seq data, we determined that lining fibroblasts express the majority of these pain-86 associated genes and, of these, we focused on genes predicted to interact with dorsal root ganglion 87 sensory nerves. This led to the discovery that synovial lining fibroblasts produce Netrin-4 (Net4 88 or NTN4), which significantly augments branching of pain-sensitive CGRP+ sensory nerves in 89 *vitro*. This work provides a novel approach to relate gene expression data to clinical data, uncovers a role for synovial fibroblast production of Netrin-4 in peripheral sensitization in RA, and 90

nominates a panel of other targets that warrant additional study for their potential role in joint pain
(Fig. S1).

93

94 **RESULTS**

95 Pain is not related to inflammation in RA patients with low inflammatory synovium

96 We categorized patients as high or low inflammatory using our previously reported histology

97 scoring algorithm (9). Consistent with our prior studies, RA pain scores were not different

98 between patients with high and low inflammatory synovium (Fig. 1A). Pain scores were

99 associated with the level of synovial inflammation as measured by the density of cells per unit of

100 tissue (cells/mm2) in patients with high inflammatory synovium, but not in patients with low

101 inflammatory synovium (Fig. 1B).

102 **GbGMI-identification of pain-associated synovial gene expression in patients with**

103 established RA

We first tested for genes that were significantly associated with pain using the usual RNA-seq 104 analysis platform, limma (14). We failed to identify any significant individual genes that were 105 106 correlated with pain suggesting the relationship of gene expression with pain could be multifactorial or nonlinear. We next hypothesized there might be groups of genes whose 107 expression varies in association with pain. We developed an iterative machine-learning Graph-108 based Gene expression Module Identification (GbGMI) computational framework to uncover a 109 110 group of genes whose expression is correlated with a given univariate clinical feature. Given a multi-modal input comprising a gene expression matrix M for m genes and n patients and an n-111 dimensional clinical feature vector *a*, GbGMI calculates the patient-to-patient similarity structure 112

according to the given clinical feature, compares that to the gene expressions using the Laplacian score, and then determines the optimal number of genes that together associate with the clinical feature through statistical tests between the t-SNE-based summary scores of the selected genes and this clinical feature (see Materials and Methods. Fig. S2).

117

118 We first benchmarked this GbGMI approach by testing whether it would correctly identify genes known to be associated with inflammation as measured by cell density, which is associated with 119 many significant individual genes as measured by limma (14). GbGMI identified a module of 120 121 2,713 genes whose gene expression summary score correlates with synovial tissue cell density (Fig. 2A-D). The positive control for this analysis was principal component one (PC1) of bulk 122 synovial RNA-seq gene expression data, which was previously shown to associate with the extent 123 124 of synovial inflammation and correlate significantly with synovial cell density (15), while the negative control was a gene expression summary score for a group of the top 5,000 most variably 125 expressed genes. As expected, PC1 scores of gene expression were significantly correlated with 126 synovial histologic cell density (Spearman $\rho=0.4$, p=0.01) (Fig. 2F) while the gene expression 127 summary score of the top 5000 most variably expressed genes were not (p=0.21) (Fig. 2E). The 128 129 gene expression summary score of the GbGMI module of 2,713 genes had a further improved correlation to synovial histologic cell density (Spearman ρ =0.59, p=0.0001) (Fig. 2G). Taken 130 131 together, this analysis indicates that GbGMI is a useful method that outperformed PCA in 132 identifying a module of genes that associate with the clinical feature of interest, synovial 133 inflammation as measured by cell density.

We next applied GbGMI to define a module of genes associated with pain in patients with low 135 inflammatory synovium. The majority of the 6,582 genes that distinguish high and low 136 137 inflammatory synovium are increased in high inflammatory synovium and are enriched for 138 pathways representing infiltrating immune cells. To uncover genes associated with pain, but not inflammation, we focused our analysis on 2,227 genes that were significantly increased in low 139 140 inflammatory synovium relative to high inflammatory synovium (9) and on pain scores that 141 document the extent of pain in the joint that was sampled (Hip Osteoarthritis Outcome Score/Knee Osteoarthritis Outcome Score (HOOS/KOOS) (Fig. 3A). The patient-reported pain 142 143 scores a were transformed into a matrix of pairwise similarity scores between patients S (Fig. 3B). We next calculated the Laplacian score (16) for each of the 2,227 low-inflammatory genes 144 145 based on its expression values (i.e., a row vector in M) and S (Fig. 3C). We then tested which 146 number of top-ranked genes collectively best correlated with pain among RA patients with low synovial inflammation and identified an 815-gene module, which we refer to as the GbGMI-147 148 identified pain-associated genes (Fig. 3D). Although the summary score of all 2,227 low inflammatory genes did not correlate with pain, summary scores of the GbGMI-identified pain-149 associated genes were significantly correlated with the patient-reported HOOS/KOOS pain in 150 151 patients with low inflammatory synovium (Fig. 3E). This correlation was not as pronounced when including all RA patients irrespective of inflammatory subset (Fig. 3F). Similar 152 153 correlations were identified when the GbGMI-identified pain-associated genes were compared to 154 Visual Analog Scores (VAS) report of pain (Fig. S3).

155 GbGMI-identified pain-associated synovial gene expression in patients with early RA

156 Overfitting is a concern in using a graph-based machine-learning approach to identify groups of

157 genes that associate with pain. It is possible that the GbGMI-identified pain-associated genes

correlate with pain in the dataset in which they were discovered, but not in other external 158 159 datasets. We next sought to test whether the pain-associated gene module identified in patients 160 with established disease was also associated with pain in a second, independent Pathobiology of Early Arthritis Cohort (PEAC) dataset (10) of synovial biopsy samples from patients with early 161 (mean of 6 months of symptoms), untreated, RA. 2,018 of the 2,227 low inflammatory genes and 162 163 738 of the 815 pain-associated genes discovered in the established RA were also measured in this dataset. The 738 GbGMI-identified pain-associated genes were also significantly correlated 164 with Visual Analog Score (VAS) pain in patients with early RA with low (fibroid or undefined) 165 inflammatory synovium (Fig. 3G), while the 2,018 low-inflammatory genes were not. In this 166 early RA cohort, the 738 GbGMI-identified pain-associated genes were also associated with pain 167 168 in all patients, irrespective of synovial inflammatory subset, as well, though the association was 169 again not as robust as was seen in those with low inflammatory synovium (Fig. 3H). Of note, the range of GbGMI summary scores decreased when all samples were included. The association of 170 171 the GbGMI-identified genes with pain was robust in the low inflammatory samples, but persisted even when all patients were included, suggesting that these genes may play a role, albeit less 172 173 pronounced, in pain in high inflammatory synovium, where inflammatory mediators are highly 174 likely to also contribute.

GbGMI-identified pain-associated genes are enriched with neurogenesis pathways and predominantly expressed by synovial fibroblasts

We next sought to understand the biological meaning and the direction of the association of the
815 GbGMI genes with pain in RA patients with low synovial inflammation. Limma was
performed to detect genes whose expression correlates with pain and genes were ranked by
limma according to this correlation. Of note, though limma did not identify any significant (FDR

<0.05) individual genes correlated with pain (Fig. S4A), as a group, expression of the 815 181 182 GbGMI-identified pain genes was significantly decreased as the HOOS/KOOS pain score 183 increased (adjusted p-value: 7.38e-12 (ks.test) (Fig. S4B and S4C), indicating a positive correlation with pain severity. The 815 pain-associated genes included ephrin (EPHA3, EPHA6, 184 EPHA7) and semaphorin (SEMA3B, SEMA3E, SEMA4C, SEMA5A, SEMA6D) family 185 186 members and were significantly enriched in nervous system development and neuron projection pathways. On the other hand, the 1,412 non-pain associated genes included CD55, PRG4, 187 CSPG4, MERTK, genes known to be involved in the normal functions of lining macrophages 188 and fibroblasts (17), and were enriched in molecular function and rRNA processing, but not 189 190 neuron projection pathways (Fig. 4A). We next examined which cells express the GbGMI painassociated genes by comparing their expression in sorted bulk synovial B cells, fibroblasts, 191 192 monocytes, and T cells, which offers high depth coverage of RNA but less cell type resolution, and sorted single cells, which offers higher cell type resolution to cell subtypes but less depth of 193 194 coverage, from the Accelerating Medicines Partnership dataset (18). Comparison of the pain-195 associated genes across sorted bulk synovial B cells, fibroblasts, monocytes, and T cells 196 indicated fibroblasts express the highest levels of pain-associated genes (Fig. 4B and 4C). We 197 reasoned pain associated genes might be more robustly expressed in fibroblasts because of a 198 relative enrichment in fibroblasts, compared to immune cells, in low-inflammatory samples. 199 However, when looking only at fibroblasts, the pain-associated genes were significantly 200 increased compared to the non-pain associated genes (Fig. 4B). The marked differences in 201 pathways enriched in pain-associated and non-pain associated genes as well as the difference in relative expression levels within fibroblasts indicates the GbGMI method did not select a random 202 group of fibroblast genes. Further analysis of the single cell RNA-seq dataset also confirmed that 203

the fibroblast subsets express the highest levels of pain-associated genes (Fig. 4D). Gene
expression analysis among fibroblast subsets indicated that, compared to the other fibroblast
subsets, lining CD55+ fibroblasts (SC-F4) express the highest level of GbGMI-identified painassociated genes (Fig. 4E). Taken together, these analyses indicate GbGMI-identified pain
associated genes are expressed by synovial fibroblasts and enriched for neurogenesis pathways.

209 Predicted interactions between lining fibroblasts and dorsal root ganglion neurons

Given the pain-associated genes were enriched in neuron projection pathways, we next explored

211 predicted interactions of pain-associated synovial fibroblast genes with dorsal root ganglion

212 (DRG) sensory neurons, which contain the soma of synovial innervating nociceptive neurons.

213 We performed receptor-ligand interaction analysis to identify predicted receptor-ligand pairs

using the pain-associated genes expressed by four synovial fibroblast subtypes in human RA

synovial tissue and genes expressed in a human DRG bulk RNA-seq dataset (19, 20). Lining

fibroblasts (SC-F4) were predicted to have the highest number of ligand-receptor interactions (57

217 SC-F4 ligands to hDRG receptors) (Fig. 5A and 5B). To further clarify which types of DRG

218 nerves might be predicted to interact with synovial fibroblasts, we also performed receptor-

219 ligand interaction analysis between the pain-associated genes expressed by the synovial

fibroblast subsets (18) and a mouse scRNA-seq DRG dataset (21). Again, lining fibroblasts (SC-

F4) were predicted to have the highest number of receptor-ligand interactions and were predicted

to interact with proprioceptors, as well as A-b, A-d and CGRP peptidergic neurons (Fig. 5C and

table S3). Comparison of the expression of 21 ligand or receptor encoding pain-associated genes

of SC-F4 revealed a gradient of pain-associated genes that are relatively lowly expressed in SC-

F1 cells and most highly expressed in SC-F4 cells, with HBEGF, CTGF, and NTN4 among the

226 most robustly expressed (Fig. 5D).

227 Products of synovial fibroblasts influence adult dorsal root ganglion sprouting and

228 branching in response to injury

229 We next sought to test whether any of the pain-associated synovial fibroblast genes, discovered in this analysis, might directly influence the growth of pain sensitive neurons in the synovium. 230 Unmyelinated, small, CGRP+ nerve fibers are responsible for pain transmission and can be 231 found in the synovium extending up to the lining layer (22), indicating synovial lining fibroblast 232 233 interaction with CGRP+ nociceptive fibers could take place within relatively close range. While pathway analysis indicated many of the pain associated genes are associated with neurogenesis, 234 the majority of this data was defined in studies of the central nervous system of developing 235 embyros of model organisms, not adult human diseased joint tissue. NTN4 was of interest 236 237 because it was associated with pain in this dataset and is highly expressed by synovial fibroblasts. Netrin-4 (NTN4 or Net4) is a secreted member of the netrin family of proteins, of 238 239 which, Netrin-1, is the first discovered and best described for its role as an axon attractant during 240 embryogenesis (23). Though Net4 has only 30% sequence homology to Netrin-1, it has been shown to augment embryonic olfactory bulb sprouting and thalamocortical branching (24-26). It 241 242 is not known whether or how Netrin-4 might influence injured adult DRG CGRP+ pain sensitive neurons. We cultured adult mouse dissociated DRG neurons with either no supplements, nerve 243 244 growth factor (Ngf), as a positive control, since it is known to produce robust effects on axon sprouting (27,28), or Net4, and measured survival, sprouting, and branching of CGRP+ DRG 245 neurons. CGRP status of the DRG neurons was assigned using immunoflourescent stains (Fig. 246 247 S4). While there was no effect of either Ngf or Net4 on CGRP+ neuron survival (Fig. 6A), or sprouting (Fig. 6B), compared to untreated CGRP+ neurons, Net4 significantly augmented 248 branching in vitro (Fig. 6B). 249

250 **DISCUSSION**

Using our newly developed GbGMI approach, we discovered a module of 815 genes, whose 251 expression correlates with patient report of pain and are enriched in neuron projection pathways. 252 253 These pain-associated genes are most robustly expressed by lining layer fibroblasts. The proteins encoded by these pain-associated genes include netrins, semaphorins, and ephrins, proteins that 254 ensure neurons and their axons develop in the correct stages and places required for normal 255 256 nervous system development. Human knee innervating sensory neurons extend their pseudounipolar axons approximately one meter from their origin in the DRG to their destination 257 in the joint. A complex interplay of multiple molecules at distinct concentrations attract or repel 258 neurons to tune their projections in space and time during development (29). Our findings that 259 260 RA synovial fibroblasts express an array of neural guidance genes that associate with patient report of pain and augment CGRP+ nociceptor growth in vitro are consistent with recent studies 261 in osteoarthritis (OA), which identified aberrant CGRP+ sensory neurite sprouting into normally 262 263 aneural cartilage (30-33). While RA tends to affect all three knee compartments similarly, OA 264 tends to affect the medial side more severely. Compared to synovial fibroblasts from the 265 nonpainful side, synovial fibroblast conditioned media from the painful side of knee OA increased neuron survival and longest branch length in vitro (34). Our studies suggest there may 266 267 be a mechanism, in both RA and OA, by which synovial fibroblasts can play a role in mediating joint pain. Our studies also led to the discovery that Netrin-4, which has been shown to affect 268 thalamocortical axon sprouting in embryogenesis(26), augments branching of injured pain-269 270 sensitive CGRP+ nerves in vitro. Netrin-4 binds the extracellular matrix molecule, laminin, specifically laminin γ 1, encoded by the gene LAMC1, and in doing so, dramatically weakens 271 matrix stiffness (25). Laminins are large glycoproteins that are abundant in synovium and 272

LAMA4 and LAMC1 expression are increased in RA synovium. It is possible that a compliant
extracellular matrix facilitates CGRP+ neurite sprouting or branching. Netrin-4 also binds cell
surface receptors, such as Unc5B (26), which are expressed on several dorsal root
ganglion. Avenues for future research include *in vivo* animal studies to test the function of
NTN4, as well as other identified pain-associated genes, and explore their potential in drug or
treatment design.

It is worth noting that there are many other genes associated with patient report of pain in this dataset that warrant additional study such as HBEGF, BTC, and CTGF, which augment neuronal sprouting in response to injury and have been used to treat pathological pain alleviation in other clinical scenarios (*35,36*). In addition, neural guidance molecules also have important functions outside the nervous system, such as affecting angiogenesis, lung branching morphogenesis, immunomodulation, and tumorogenesis, and these non-neuronal effects of this family of molecules warrant further study in the context of arthritis.

In summary, here we present GbGMI, a feature-selection method that can be used to identify pathology-specific multi-gene signatures by exploiting patient-to-patient similarity structures in different feature spaces when the number of patients is limited. We used GbGMI to identify pain-associated genes expressed by synovial fibroblasts in low-inflammatory RA synovial tissues, leading to the discovery that synovial fibroblast-sensory neuron crosstalk may relate noninflammatory joint pain and providing an avenue to pursue novel targets for the management of joint pain.

293 MATERIALS AND METHODS

294 Study Approval

This study includes data from 102 RA patients undergoing arthroplasty at the Hospital for 295 Special Surgery (HSS) in New York. All patients met either the American College of 296 297 Rheumatology (ACR)/European League Against Rheumatism 2010 Classification criteria (37) and/or the ACR 1987 criteria for RA. Patient data including Knee disability and Osteoarthritis 298 Outcome Score (KOOS) (38) and Hip disability and Osteoarthritis Outcome Score (HOOS) (39) 299 300 questionnaire were collected. RA pain scores indicate response to the question "How much pain have you felt due to your rheumatoid arthritis during the last week?", with responses ranging 301 from 1 to 10. Condition pain scores indicate response to the question, "How much pain have you 302 had because of your condition OVER THE PAST WEEK? Please indicate how severe your pain 303 has been" with responses ranging from 1 to 10. This study was approved by the HSS Institutional 304 305 Review Board (approval no. 2014-233), the Rockefeller University Institutional Review Board 306 (approval no. DOR0822), and the Biomedical Research Alliance of New York (approval no. 15-08-114-385). All participating patients provided their signed informed consent. 307

308 H&E Histologic Scoring

Synovial samples were obtained from the most grossly inflamed (dull and opaque) area of 309 310 synovium. If there were no obviously inflamed areas, samples were obtained from standard 311 locations: the femoral aspects of the medial and lateral gutters and the central supratrochlear region 312 of the suprapatellar pouch. Each tissue biopsy was sectioned at 5-micrometer thickness and stained 313 with Harris modified hematoxylin solution and eosin Y (H&E) manufactured by Epredia in Kalamazoo, MI. An expert musculoskeletal pathologist scored fourteen synovial histologic 314 features in a single section for each patient: lymphocytic inflammation, mucoid change, fibrosis, 315 316 fibrin, germinal centers, lining hyperplasia, neutrophils, detritus, plasma cells, binucleated plasma cells, Russell bodies, sub-lining giant cells, synovial lining giant cells, and mast cells. Detailed 317

methods for scoring these features are described in prior studies (9,40) and available at www.hss.edu/pathology-synovitis, the classification algorithm is available at Immport www.immport-open/public/study/displayStudyDetail/SDY1299.

321 Gene Expression Established Arthritis Cohort

RNA was extracted from 39 bulk synovial tissue samples collected from an established RA 322 323 cohort and previously sequenced as described in (41) (ImmPort Accession #SDY1299). In brief, these libraries were prepared using TruSeq messenger RNA (mRNA) Stranded Library kits, 50-324 325 bp paired-end reads were sequenced on a HiSeq2500 platform, and reads were aligned to hg19 326 using STAR (42). Samples with >0.1% globin mRNA were excluded from further analysis. After 327 quality control, ComBaT in the Bioconductor SVA package (43) was used for batch effect 328 correction, and DESeq2 (44) was used to normalize the data. Consensus clustering identified three gene expression clusters characterized by different levels of synovial inflammation: low 329 (n=14), intermediate (n=11), and high (n=14) (9). Of these 39 RA patients, 38 had mean nuclei 330 331 density data for the benchmarking analysis (15), and 26 had low inflammatory synovium, for which all 26 had scores for lymphocytic inflammation and lining hyperplasia and 22 had scores 332 333 of fibrosis and HOOS/KOOS pain scores. We used limma (14) to test for gene expression correlates of fibrosis, lymphocytic inflammation, lining hyperplasia and pain. 334

335 Gene-set enrichment analysis (GSEA)

A moderated t-test was performed between each gene expression profile and the pain scores over the subset (n=22) low-inflammatory patients. The resulting log2 fold-change therefore offers a score of correlation between the expression of each gene and the pain. The moderated t-statistic (ratio of log2-fold change to its standard error) was used to rank the genes. The fgsea R package (45) was used for enrichment analysis of the GbGMI-identified subset (n=815) of genes

- associated with pain as well as the set of marker genes for each of the 18 synovial cell
- subpopulations (200 marker genes per subpopulation) (11,18) (ImmPort Accession #SDY998).
- 343 Since the HOOS/KOOS pain scores are from 0 (worst joint health) to 100 (best joint health)
- (38,39,46), a gene set more correlated to the bottom of the list hence negatively correlated with
- 345 HOOS/KOOS pain scores, indicating positive correlation with pain.

346 Gene Expression Early Arthritis Cohort

- For external validation of the pain-associated genes identified by our method, we downloaded the
- bulk RNA-seq of early RA patients from the Pathobiology of Early Arthritis Cohort (PEAC) on
- 349 ArrayExpress (https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-6141/samples/)
- Using only sample with sufficient data quality, reads were pseudoaligned to hg38 with Kallisto
- in order to generate a counts matrix. Counts were normalized for read depth (counts into
- log2(CPM+1) (Counts Per Million)) and batch corrected using removeBatchEffect from limma.

353 Gene Expression in bulk sorted cells and single cells

- In the analyses related to RA synovial cell types, we used the sorted-population bulk RNA-seq
- 355 gene expression data of the synovial T cells (CD45+, CD3+, CD14–), monocytes (CD45+, CD3–
- 356 , CD14+), B cells (CD45+, CD3-, CD14-, CD19+), and fibroblasts (CD45-, CD31-, PDPN+)
- collected by fluorescence activated cell sorting (BD FACSAria Fusion) directly in buffer RLT
- (Qiagen) (11,18). Normalized read counts per gene as transcripts per million (TPMs) were used
- 359 (ImmPort Accession #SDY998) (11).

360

We used the single-cell RNA-seq data preprocessed by (*18*), where the gene expression levels were quantified by counting UMIs (Unique Molecular Identifiers) and transformed into

363	log2(CPM +	1)	. From the scRNA	A-seq	profiles for 32	2,391 g	genes and 5.265	cells left	after rigor	rous
	- (7) (-					2				

- quality control, 18 unique cell populations were identified by an integrated strategy based on
- canonical correlation analysis. Specifically, in fibroblasts: CD34+ sublining fibroblasts (SC-F1),
- 366 HLA-DRAhi sublining fibroblasts (SC-F2), DKK3+ sublining fibroblasts (SC-F3), and CD55+
- lining fibroblasts (SC-F4); in monocytes: IL1B+ pro-inflammatory monocytes (SC-M1),
- NUPR1+ monocytes (SC-M2), C1QA+ monocytes (SC-M3), and interferon (IFN) activated
- 369 monocytes (SC-M4); in T cells: three CD4+ clusters: CCR7+ T cells (SC-T1), FOXP3+
- regulatory T cells (Treg cells) (SC-T2), and PDCD1+ TPH and TFH (SC-T3) cells, and three
- 371 CD8+ clusters, GZMK+ T cells (SC-T4), GNLY+GZMB+ cytotoxic lymphocytes (CTLs) (SC-
- 372 T5), and GZMK+GZMB+ T cells (SC-T6); in B cells: naïve IGHD+CD27–(SC-B1),
- 373 IGHG3+CD27+ memory B cells (SC-B2), autoimmune-associated B cell (ABC) cluster (SC-B3)
- with high expression of ITGAX (also known as CD11c) and a plasmablast cluster (SC-B4) with
- high expression of immunoglobulin genes and XBP1 (18). The top 200 marker genes for each
- subpopulation identified by differential expression analysis in the original publication (18) were
- 377 used as signature genes for individual cell-types within RA synovium.

378 Description of our Graph-based Gene expression Module Identification (GbGMI)

379 framework

We developed GbGMI, a graph-based machine learning framework of algorithms, to identify a gene expression module that strongly correlates with pain in low-inflammatory RA synovial tissues (Fig. S2). We use $M \in R^{m \times n}$ to represent the input gene expression matrix of genes and patients. We use a numeric vector $a \in R^n$ to represent the pain scores reported by these patients. We quantified the quality Q of a selected gene subset via the correlation between their collective expression and the pain score, and then searched for a gene subset with optimal quality Q as a

feature selection task (47-50). As exhaustive search through all possible subsets of an input gene 386 set to optimize Q is computationally intractable (51), we adapted and integrated the feature 387 scoring strategy used in the filter feature-selection/ranking approaches (52-54) and the feature 388 subset scoring strategy used in the wrapper feature-selection approaches (50,55). Specifically, we 389 390 generated a gene prioritization list \mathcal{L}_s according to how well each individual gene expression respects the geometric structure over patients built according to their pain scores. Then, the 391 392 quality Q_k of the k-th candidate gene subset comprising the top k genes in \mathcal{L}_s is evaluated, for k ranging from 1 to m. The first k^* where Q_k peaked is used as the cut-off point on \mathcal{L}_s . This 393 subset of k^* genes is the output pain-associated gene module. 394

395

Gene prioritization with adapted Laplacian Score algorithm. (16) Given the input gene 396 expression matrix and pain-score vector, we ranked the genes by the way each gene expression 397 vector (i.e., a row vector in the gene expression matrix M) respected a given geometric structure 398 over the patients encoded in an $n \times n$ similarity matrix S based on the pain score vector a 399 instead of assuming independent observations in the correlation tests (Fig. S2, step A). To 400 compute S, a Gaussian kernel, which empirically outperformed other types of kernels (56, 57), 401 was adopted to map the Euclidean distance between the pain scores of each pair of patients and 402 into a similarity measure $S(i, j) \in [0, 1]$: 403

$$S(i,j) = e^{-\frac{|a(i) - a(j)|^2}{h}}$$
(1)

where *h* corresponds to the bandwidth or smoothing factor in a kernel metric definition. This formulation forces the similarity measure between any two patients with significantly different pain scores to be close to 0, while pushing the similarity measure between the patients of pain scores within a certain range (depending on the smoothing factor) to be closer to 1. This

promotes the *locality* we want to focus on. We set *h* to control the local neighborhood of patients on graph *S* according to the theoretical range of the pain scores (e.g., h = 100 for HSS HOOS/KOOS pain score or PEAC VAS characteristic since either ranges between 0 and 100).

412 The Laplacian Score of each gene is then computed to evaluate how well this gene's expression on these patients preserves S. (Fig. S2, step B.) This is different from the original publication 413 414 (16,58) which aimed to preserve the input feature space (e.g., the input low-inflammatory genes), wherein we aim to select features (e.g., the k^* pain-associated genes). The Laplacian matrix of S 415 is defined by L = D - S, where D is a diagonal matrix with D_{ii} indicating the degree of node 416 (i.e., patient) *i* in the weighted graph S (i.e., D = diag(S 1)). For the *r*-th gene, let $M_{r,*}$ be its *n*-417 dimensional gene expression vector across the patients (i.e., the *r*-th row vector in the gene 418 expression matrix M), its Laplacian Score ls(r) is computed as: 419

$$ls(r) = \frac{\widehat{m_r}^T L \widehat{m_r}}{\widehat{m_r}^T D \widehat{m_r}}, \widehat{m_r} = M_{r,*}^T - \frac{M_{r,*}D1}{1^T D 1} 1$$
(2)

where the symbol 1 denotes a column vector whose all elements are 1's with dimensionality determined by context. The gene prioritization list \mathcal{L}_s is generated by sorting the input *m* genes according to their Laplacian Scores in ascending order. The smaller the Laplacian Score of a gene, the better its expression data respect the geometric structure defined by *S* over the patients (according to objective function analysis (16)). Each top-*k* subset on \mathcal{L}_s forms a candidate gene subset for selection. The rows of *M* were reordered according to \mathcal{L}_s . (Fig. S2, step C.)

426

427 *Quantification of candidate k-gene subset quality* Q_k . *The* Q_k *of the* k*-th candidate* gene subset 428 is measured based on the association between their collective expression pattern and the pain-

score vector a. Given the gene expression submatrix $M_{1:k,*}$ of this candidate k-gene subset, Q_k is 429 430 computed through two steps: Firstly, project the k-gene expression vector of each patient into a univariate summary score that preserves the patient-to-patient similarity structure in the original 431 k-dimensional feature (gene) space. This addresses the dimensionality mismatch between the 432 multi-gene expression and the univariate patient-level pain score (9). The resulting summary 433 score vector of the *n* patients is denoted s_k . (Fig. S2, step D.) Secondly, quantify Q_k by using 434 the statistical significance of correlation test (e.g., the -log(p-value) of Kendall's correlation 435 test) between s_k and a over the same patients. We chose the first k^* , where Q_{k^*} peaked, as the 436 cut-off point on the sorted gene prioritization list \mathcal{L}_s . This subset of k^* genes is the pain-437 associated gene module identified by our GbGMI framework. (Fig. S2, step E.) 438 439

441 (57). The resulting summary score vector s_k for the *n* patients respect how the gene expression 442 data was arranged in the *k*-gene feature space of this candidate gene subset. We hereon briefly 443 sketch the instantiation of t-SNE with the variables involved in our study. Following the SNE 444 framework (59), the directional similarity of patient *j* to patient *i* based on their multi-gene 445 expression vectors $M_{1:k,i}$ and $M_{1:k,j}$ is :

For Fig. S2, step D, We used the t-distributed Stochastic Neighborhood Embedding (t-SNE)

$$p(j|i) = \frac{exp(-||M_{1:k,i} - M_{1:k,j}||^2/2\sigma_i^2)}{\sum_{l \neq i} exp(-||M_{1:k,i} - M_{1:k,l}||^2/2\sigma_i^2)}$$
(3)

446

440

447 where the variance of the Gaussian kernel σ_i^2 is chosen such that the perplexity of the 448 conditional probability distribution over all points $j \neq i$ defined by

$$Perp(P_i) = 2H(P_i), H(P_i) = -\Sigma_j P(j|i) \log_2 p(j|i)$$
(4)

449

matches a pre-specified value. The perplexity in this context can be interpreted as an estimation
about the number of close neighbors of each patient on graph *S*. Therefore, we specify the
perplexity based on the rounded mean degree of the similarity graph *S* built from *a*. The
symmetric SNE was used for mathematical and computational convenience in the t-SNE
formulation by defining the following undirected similarities:

$$p(i,j) = \frac{p(j|i) + p(i|j)}{2n}$$
(5)

455

where *n* is the number of patients. Since $\Sigma_{i,j}p(i,j) = 1$, this is a valid probability distribution on the set of all pairs (i,j). The t-SNE step in this algorithm uses the t-distribution with one degree of freedom (also known as Cauchy distribution) as the one-dimensional similarity kernel applied to pairs of summary scores defined by:

$$q(i,j) = \frac{(1+||s(i)-s(j)||^2)^{-1}}{\sum_{k\neq l} (1+||s(k)-s(l)||^2)^{-1}}$$
(6)

The main idea of this t-SNE-based step is to arrange the patients in a one-dimensional space such that the similarities q(i, j) between s(i) and s(j) match p(i, j) as close as possible in terms of the Kullback-Leibler (KL) divergence. Thus the loss function is:

$$L = \Sigma_{i,j} p(i,j) \log \frac{p(i,j)}{q(i,j)}$$
⁽⁷⁾

463

A summary score vector s_k is computed for each candidate *k*-gene subset, rendering a set of *m* such vectors $\{s_k | k = 1, 2, \dots, m\}$.

467 Our framework GbGMI can be applied to identify a subset of genes that collectively associate
468 with some other patient-level numeric attribute beyond the main focus of this paper (the
469 HOOS/KOOS pain score). Our framework is also flexible and adaptive in different contexts by
470 replacing specific computational components with other design choices (e.g., other embeddings
471 instead of t-SNE for computing summary scores of selected gene expression).

472 Pathway Enrichment Analysis

473 We used g:Profiler (https://biit.cs.ut.ee/gprofiler/gost) (60) for enrichment analysis of genes in

474 the KEGG (61), REACTOME (62), WikiPathways pathways (63), and the Gene Ontology (GO):

475 molecular functions (MF), cellular components (CC) and biological processes (BP) gene sets

476 (64). A hypergeometric test was performed to estimate statistical significance, and all P values

477 were adjusted for multiple testing using g:SCS (Set Counts and Sizes) correction (65). The genes

from the bulk RNA-seq data (ImmPort Accession #1299) (9) were used to custom the statistical

domain scope (i.e., background gene list), the size of which describes the total number of genes

used for random selection and is one of the four parameters for the hypergeometric probability

481 function for computing statistical significance used in g:GOSt (60).

482 Ligand-receptor Interaction Analysis

479

For predicting potential ligand-receptor interactions between RA synovium and DRG, we used the normalized counts per gene as transcripts per million (TPMs) reported in a prior study where human DRG tissue samples were sequenced using bulk RNA-seq and analyzed (20). We used the scRNA-seq data from a mouse DRG dataset (21) to generate the transcriptome profiles of individual cell-types within DRG. Our analysis used the expression values and metadata for each subpopulation of component cells provided in the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) databases (#GSE139088) generated by

 specifically 15 somatosensory neuron subtypes (Aβ field/SA1, Aβ RA-LTMR, Aδ-LTMR, C- LTMR, CGRP-α, CGRP-ε, CGRP-η, CGRP-γ, CGRP-θ, CGRP-ζ, Nonpeptidergic nociceptors, TrpM8, Proprioceptors, SST, Cold thermoceptors) and a cluster of unassigned/non-neuronal cells (21). 	490	the original publication. The cell subpopulations in this mDRG scRNA-seq dataset are
 LTMR, CGRP-α, CGRP-ε, CGRP-η, CGRP-γ, CGRP-θ, CGRP-ζ, Nonpeptidergic nociceptors, TrpM8, Proprioceptors, SST, Cold thermoceptors) and a cluster of unassigned/non-neuronal cells (21). 	491	specifically 15 somatosensory neuron subtypes (A β field/SA1, A β RA-LTMR, A δ -LTMR, C-
 TrpM8, Proprioceptors, SST, Cold thermoceptors) and a cluster of unassigned/non-neuronal cells (21). 	492	LTMR, CGRP-α, CGRP-ε, CGRP-η, CGRP-γ, CGRP-θ, CGRP-ζ, Nonpeptidergic nociceptors,
494 (21).	493	TrpM8, Proprioceptors, SST, Cold thermoceptors) and a cluster of unassigned/non-neuronal cells
	494	(21).

495

For ligand-receptor analysis, we used the ligand-receptor pair interactome containing more than 3,000 interactions (denoted I^o) created by a previous publication (19). This prior model mapped the potential ligand-receptor interactions between DRG neurons and distinct cell types within tissues throughout the human body by curating a database of ligand and receptor pairs across the genome, based on the literature and curated bioinformatics databases (66–71).

501

502 To identify the interactome for a specific ordered pair of tissue or cell types, the ligand-encoding genes from I^{o} were intersected with the genes that satisfy the ligand-side inclusion criteria in the 503 tissue or cell type wherein we investigate the upstream component of the signaling. Similarly the 504 receptor-encoding genes of I^o were intersected with the genes satisfying the receptor-side 505 inclusion criteria in the tissue or cell type wherein we investigate the downstream component of 506 the signaling. We generated the interactomes in two different contexts: (i) between each of the 4 507 fibroblast subtypes in human RA synovial tissue and the human DRG (hDRG) (20) and (ii) 508 between each of the 4 synovial fibroblast subtypes and each of the 14 neuronal cell types of 509 mouse DRG (mDRG) (21, 41) (GEO GSE139088). We set the filtering criteria to consider a 510 confined subset of genes from the bulk or single-cell RNA-seq data in a specific tissue or cell 511 type depending on the data available and the question being asked in each context. In particular: 512

513	For each fibroblast subtype in human RA synovial tissue, we included its top 200 marker genes
514	(18) intersected with the GbGMI-identified 815 pain-associated genes. From the hDRG bulk
515	RNA-seq data, we included the genes consistently expressed (> 0.1 TPM) in the 16 human DRG
516	samples with "yes" for their associated pain status (20). On the mDRG scRNA-seq data, we
517	included the differentially expressed genes (adjusted p-value < 0.05) identified by the
518	FindMarkers function from the R package Seurat (72) for each of the 15 neuronal cell
519	subpopulations compared to the rest. Lastly, the ligand(/receptor)-coding genes with 0
520	corresponding receptor(/ligand)-coding genes were excluded from the built interactome.
521	
522	We also performed ligand-receptor interaction analysis between the pain-associated genes
523	expressed by the four synovial fibroblast subtypes and a scRNA-seq dataset of adolescent mouse
524	nervous system (MNS) (73). We predicted considerable connections between lining fibroblasts
525	(SC-F4) and peripheral sensory neurofilament, peptidergic and non-peptidergic neurons, as well
526	as sympathetic cholinergic and noradrenergic neurons (Fig. S6). These analyses are detailed in
527	Supplementary Materials.
528	DRG Dissection and Digestion
529	Prior to extraction of the DRG neurons, chambered coverslips (ibidi 80286) were coated
530	overnight at 37°C with poly-1-lysine (Sigma-Aldrich P4832) and then for two hours at 37°C with
531	mouse sarcoma basement membrane laminin (Sigma-Aldrich L2020) diluted 1:50 with 1XPBS
532	and, with one also coated with 0.2µg/mL hNet4 (R&D Systems 1254-N4).

533

534 For each assay, sensory DRG neurons were harvested from two female 6-8 week old C57BL/6

535 mice (Jackson Laboratories), under a dissection microscope using forceps and placed into a

536	waiting 15mL conical tube on ice containing 1X L-15 medium (ThermoFisher 21083027). DRGs
537	were spun down at 950 rpm for two minutes. Media was aspirated and replaced with 1mL L-15
538	containing 10mg/mL Dispase II (Sigma-Aldrich 04942078001) and 10mg/mL Collagenase IV
539	(ThermoFisher 17104019). DRGs were then placed at 37°C for 20 minutes. Enzyme solution was
540	then carefully aspirated and replaced with 2mL L-15. Pellet was resuspended thoroughly with a
541	1000ul pipette. 25ul 10mg/mL DNAse I was then added and once again the cells were placed at
542	37°C for 20 minutes. The cells were then spun down for 5 minutes at 950 rpm and resuspended
543	in 5mL L-15. After another 5 minute centrifugation, the cells were resuspended in 1mL L-15 and
544	layered on top of 15% ice-cold BSA (Sigma-Aldrich A7906) and spun down at room
545	temperature for 8 minutes at 1179 rpm to remove myelin. The cell pellet was resuspended in 1X
546	Neurobasal Plus media (ThermoFisher A3582901) containing B27 (ThermoFisher 17504001)
547	diluted 1:50, glutaMAX (ThermoFisher 35050061) diluted 1:100, and gentamicin sulfate (Abbott
548	Laboratories), and then plated onto the pre-coated slides. 0.1ug/mL human beta-NGF (R&D
549	Systems 256-GF) was added to the media of the positive control slide chamber.
550	Immunofluorescence Staining
551	After 24 hours, cells were fixed with 4% PFA (Electron Microscopy Sciences 15714-S) for 10
552	minutes at room temperature and then permeabilized with 0.2% Triton on ice. They were then
553	blocked with 3% BSA for 1 hour at RT, then incubated at 4°C overnight with primary antibodies

- rabbit anti-CGRP (Immunostar 24112) diluted 1:20,000 and mouse anti-beta III tubulin (abcam
- ab78078) diluted 1:1000 in 3% BSA. The next day, cells were incubated with secondary
- antibodies goat anti-Mouse Alexa Fluor 555 (ThermoFisher A21422) and goat anti-Rabbit Alexa
- 557 Fluor 488 (ThermoFisher A11008), both diluted 1:1000, for two hours at room temperature.

- 558 Following the second incubation, plates were washed three times in 1XPBS, with the second
- wash containing DAPI (ThermoFisher D1306) diluted 1:1000.

560 Neurite Imaging, Quantification, and Comparison

Each chambered slide was examined under a Keyence fluorescence microscope and the 561 accompanying software was used to capture a stitched image of a large 5x5 area randomly 562 selected on the plate at 10X magnification. Five of these images were captured per plate. To 563 564 quantify sprouting versus non-sprouting DRG neurons, each image was examined in ImageJ and used the Cell Counter plugin to keep track of the total number of sprouting neurons, identified as 565 having at least three neurites extended from the cell body where the extensions were more than 566 twice the diameter of the cell body and exhibited some degree of branching. From across these 567 568 images, n=10 neurons that exhibited branching were selected and their branching was quantified using the Sholl Analysis plugin. Each analysis used a start radius of 30 pixels, an end radius of 569 570 225 pixels, and a step size of 7. Mixed model repeated measures analysis was used to analyze 571 Sholl data. The model included group, radius (categorical), and group*radius interaction as fixed effects. A significant group*radius interaction indicated group differences and branching. 572

573 List of Supplementary Materials

574 Materials and Methods

- 575 Identify differentially expressed genes via ANOVA test on pain-level-based groupings
- 576 Ablation study of GbGMI using alternative approaches for gene prioritization
- 577 Sensitivity analysis of GbGMI on the HSS low-inflammatory patients
- 578 Methodological Validation of GbGMI on the early RA dataset
- 579 Ligand-receptor analysis using mouse nervous system scRNA-seq

- 580 **Fig S1** Overview of Study.
- 581 Fig S2 A diagram illustrating the framework of GbGMI for identifying a synovial gene
- 582 expression signature that associates with pain.
- 583 Fig S3 GbGMI-identified pain-associated synovial gene expression compared against VAS pain
- scores in patients with established RA at different levels of synovial inflammation.
- 585 **Fig S4** GbGMI-identified pain-associated gene expression increases with increasing pain
- 586 severity.
- 587 **Fig S5** Representative staining of CGRP+ DRG neuron *in vitro*.
- **Fig S6** Sensitivity analysis of GbGMI on the HSS low-inflammatory patients.
- **Fig S7** Potential ligand-receptor interactions between synovial fibroblasts and neurons in the
- 590 mouse nervous system.
- 591 **Tables S1** Pathway Analysis
- 592 **Tables S2** Fibroblast–DRG receptor ligand interaction analysis
- 593 **Tables S3** Fibroblast-Sensory nerve subset receptor ligand interaction analysis
- 594 **Data file S1** Data file S1 Pathway Analysis.xlsx
- 595 **Data file S2** Data file S2 Fibroblast DRG receptor ligand interaction analysis.xlsx
- 596 **Data file S3** Data file S3 Fibroblast-Sensory nerve subset receptor ligand interaction

597 analysis.xlsx

598 **References and Notes**

599 1. Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev

- 600 Neurosci. 2005 Jul;6(7):521–32.
- Alivernini S, Firestein GS, McInnes IB. The pathogenesis of rheumatoid arthritis. Immunity.
 2022 Dec 13;55(12):2255–70.
- 3. Nagy G, Roodenrijs NM, Welsing PM, Kedves M, Hamar A, van der Goes MC, et al.
- EULAR definition of difficult-to-treat rheumatoid arthritis. Ann Rheum Dis. 2021
 Jan;80(1):31–5.
- 4. Lee YC, Frits ML, Iannaccone CK, Weinblatt ME, Shadick NA, Williams DA, et al.
- Subgrouping of patients with rheumatoid arthritis based on pain, fatigue, inflammation, and
 psychosocial factors. Arthritis Rheumatol. 2014 Aug;66(8):2006–14.
- 5. McWilliams DF, Rahman S, James RJE, Ferguson E, Kiely PDW, Young A, et al. Disease

activity flares and pain flares in an early rheumatoid arthritis inception cohort;

characteristics, antecedents and sequelae. BMC Rheumatol. 2019 Nov 18;3:49.

- 6. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis
 reflects pain, not disease activity. Rheumatology . 2006 Jul;45(7):885–9.
- 614 7. Stebbings S, Herbison P, Doyle TCH, Treharne GJ, Highton J. A comparison of fatigue

correlates in rheumatoid arthritis and osteoarthritis: disparity in associations with disability,

- anxiety and sleep disturbance. Rheumatology . 2010 Feb;49(2):361–7.
- 8. Buch MH, Eyre S, McGonagle D. Persistent inflammatory and non-inflammatory
- 618 mechanisms in refractory rheumatoid arthritis. Nat Rev Rheumatol. 2021 Jan;17(1):17–33.
- 619 9. Orange DE, Agius P, DiCarlo EF, Robine N, Geiger H, Szymonifka J, et al. Identification of

620		Three Rheumatoid Arthritis Disease Subtypes by Machine Learning Integration of Synovial
621		Histologic Features and RNA Sequencing Data. Arthritis Rheumatol. 2018 May;70(5):690-
622		701.
623	10.	Lewis MJ, Barnes MR, Blighe K, Goldmann K, Rana S, Hackney JA, et al. Molecular
624		Portraits of Early Rheumatoid Arthritis Identify Clinical and Treatment Response
625		Phenotypes. Cell Rep. 2019 Aug 27;28(9):2455–70.e5.
626	11.	Dennis G Jr, Holweg CTJ, Kummerfeld SK, Choy DF, Setiadi AF, Hackney JA, et al.
627		Synovial phenotypes in rheumatoid arthritis correlate with response to biologic therapeutics.
628		Arthritis Res Ther. 2014 Apr 30;16(2):R90.
629	12.	Humby F, Lewis M, Ramamoorthi N, Hackney JA, Barnes MR, Bombardieri M, et al.
630		Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy
631		and predict radiographic progression in early rheumatoid arthritis patients. Ann Rheum Dis.
632		2019 Jun;78(6):761–72.
633	13.	Nerviani A, Di Cicco M, Mahto A, Lliso-Ribera G, Rivellese F, Thorborn G, et al. A Pauci-
634		Immune Synovial Pathotype Predicts Inadequate Response to $TNF\alpha$ -Blockade in
635		Rheumatoid Arthritis Patients. Front Immunol. 2020 May 5;11:845.
636	14.	Ritchie ME, Phipson B, Wu D, Hu Y, Law CW, Shi W, et al. limma powers differential
637		expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015
638		Apr 20;43(7):e47.
639	15.	Guan S, Mehta B, Slater D, Thompson JR, DiCarlo E, Pannellini T, et al. Rheumatoid
640		Arthritis Synovial Inflammation Quantification Using Computer Vision. ACR Open

641	Rheumatol. 2022 Apr;4(4):322–31.	
-----	----------------------------------	--

642	16. He X, Cai D, Niyogi P. Laplacian Score for Feature Selection. Adv Neural Inf Process Syst
643	[Internet]. 2005 [cited 2023 Jul 6];18. Available from:

644 https://proceedings.neurips.cc/paper_files/paper/2005/file/b5b03f06271f8917685d14cea7c6

645 c50a-Paper.pdf

- Alivernini S, MacDonald L, Elmesmari A, Finlay S, Tolusso B, Gigante MR, et al. Distinct
 synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid
 arthritis. Nat Med. 2020 Aug;26(8):1295–306.
- 18. Zhang F, Wei K, Slowikowski K, Fonseka CY, Rao DA, Kelly S, et al. Defining
- 650 inflammatory cell states in rheumatoid arthritis joint synovial tissues by integrating single-

cell transcriptomics and mass cytometry. Nat Immunol. 2019 Jul;20(7):928–42.

- 19. Wangzhou A, Paige C, Neerukonda SV, Naik DK, Kume M, David ET, et al. A ligand-
- receptor interactome platform for discovery of pain mechanisms and therapeutic targets. Sci
- 654 Signal [Internet]. 2021 Mar 16;14(674). Available from:
- 655 http://dx.doi.org/10.1126/scisignal.abe1648
- 20. North RY, Li Y, Ray P, Rhines LD, Tatsui CE, Rao G, et al. Electrophysiological and
- transcriptomic correlates of neuropathic pain in human dorsal root ganglion neurons. Brain.
 2019 May 1;142(5):1215–26.
- 659 21. Sharma N, Flaherty K, Lezgiyeva K, Wagner DE, Klein AM, Ginty DD. The emergence of
 660 transcriptional identity in somatosensory neurons. Nature. 2020 Jan;577(7790):392–8.
- 661 22. Mapp PI, Walsh DA, Garrett NE, Kidd BL, Cruwys SC, Polak JM, et al. Effect of three

662		animal models of inflammation on nerve fibres in the synovium. Ann Rheum Dis. 1994
663		Apr;53(4):240–6.
664	23.	Serafini T, Kennedy TE, Galko MJ, Mirzayan C, Jessell TM, Tessier-Lavigne M. The
665		netrins define a family of axon outgrowth-promoting proteins homologous to C. elegans
666		UNC-6. Cell. 1994 Aug 12;78(3):409–24.
667	24.	Koch M, Murrell JR, Hunter DD, Olson PF, Jin W, Keene DR, et al. A novel member of the
668		netrin family, beta-netrin, shares homology with the beta chain of laminin: identification,
669		expression and functional characterization. J Cell Biol. 2000 Oct 16:151(2):221–34
007		
670	25.	Reuten R, Patel TR, McDougall M, Rama N, Nikodemus D, Gibert B, et al. Structural
671		decoding of netrin-4 reveals a regulatory function towards mature basement membranes. Nat
672		Commun 2016 Nov 30:7:13515
072		Commun. 2010 Nov 50,7.15515.
673	26.	Hayano Y, Sasaki K, Ohmura N, Takemoto M, Maeda Y, Yamashita T, et al. Netrin-4
674		regulates thalamocortical axon branching in an activity-dependent fashion. Proc Natl Acad
074		
675		Sci U S A. 2014 Oct 21;111(42):15226–31.
676	27.	Lindsay RM. Nerve growth factors (NGF, BDNF) enhance axonal regeneration but are not
	_,,	
677		required for survival of adult sensory neurons. J Neurosci. 1988 Jul;8(7):2394–405.
678	28.	Denk F, Bennett DL, McMahon SB. Nerve Growth Factor and Pain Mechanisms. Annu Rev
		Numeral: 2017 I1 25:40:207-25
679		Neurosci. 2017 Jul 25;40:307–25.

Aalkjær C, Nilsson H, De Mey JGR. Sympathetic and Sensory-Motor Nerves in Peripheral
Small Arteries. Physiol Rev. 2021 Apr 1;101(2):495–544.

682	30.	Gonçalves Dos Santos G, Jimenéz-Andrade JM, Woller SA, Muñoz-Islas E, Ramírez-Rosas
683		MB, Ohashi N, et al. The neuropathic phenotype of the K/BxN transgenic mouse with
684		spontaneous arthritis: pain, nerve sprouting and joint remodeling. Sci Rep. 2020 Sep
685		24;10(1):15596.
686	31.	Obeidat AM, Miller RE, Miller RJ, Malfait AM. The nociceptive innervation of the normal
687		and osteoarthritic mouse knee. Osteoarthritis Cartilage. 2019 Nov;27(11):1669–79.
688	32.	Aso K, Shahtaheri SM, Hill R, Wilson D, McWilliams DF, Nwosu LN, et al. Contribution
689		of nerves within osteochondral channels to osteoarthritis knee pain in humans and rats.
690		Osteoarthritis Cartilage. 2020 Sep;28(9):1245–54.
691	33.	Zhu S, Zhu J, Zhen G, Hu Y, An S, Li Y, et al. Subchondral bone osteoclasts induce sensory
692		innervation and osteoarthritis pain. J Clin Invest. 2019 Mar 1;129(3):1076–93.
693	34.	Nanus DE, Badoume A, Wijesinghe SN, Halsey AM, Hurley P, Ahmed Z, et al. Synovial
694		tissue from sites of joint pain in knee osteoarthritis patients exhibits a differential phenotype
695		with distinct fibroblast subsets. EBioMedicine. 2021 Oct;72:103618.
696	35.	Borges JP, Mekhail K, Fairn GD, Antonescu CN, Steinberg BE. Modulation of Pathological
697		Pain by Epidermal Growth Factor Receptor. Front Pharmacol. 2021 May 12;12:642820.
698	36	Wang Y. Zhang F. Zhang Y. Shan O. Liu W. Zhang F. et al. Betacellulin regulates
699	50.	peripheral nerve regeneration by affecting Schwann cell migration and axon elongation. Mol
700		Med. 2021 Mar 25:27(1):27.
701	37.	Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd, et al. 2010
702		Rheumatoid arthritis classification criteria: an American College of

703	Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis
704	Rheum. 2010 Sep;62(9):2569-81.

- 38. Roos EM, Roos HP, Lohmander LS, Ekdahl C, Beynnon BD. Knee Injury and Osteoarthritis
- 706 Outcome Score (KOOS)--development of a self-administered outcome measure. J Orthop
- 707 Sports Phys Ther. 1998 Aug;28(2):88–96.
- 39. Nilsdotter AK, Lohmander LS, Klässbo M, Roos EM. Hip disability and osteoarthritis
- 709 outcome score (HOOS)--validity and responsiveness in total hip replacement. BMC
- 710 Musculoskelet Disord. 2003 May 30;4:10.
- 40. Orange DE, Agius P, DiCarlo EF, Mirza SZ, Pannellini T, Szymonifka J, et al. Histologic
- and Transcriptional Evidence of Subclinical Synovial Inflammation in Patients With
- 713 Rheumatoid Arthritis in Clinical Remission. Arthritis Rheumatol. 2019 Jul;71(7):1034–41.
- 41. Fraenkel L, Bathon JM, England BR, St Clair EW, Arayssi T, Carandang K, et al. 2021
- American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.
- 716 Arthritis Care Res . 2021 Jul;73(7):924–39.
- 42. Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, et al. STAR: ultrafast
 universal RNA-seq aligner. Bioinformatics. 2013 Jan 1;29(1):15–21.
- 43. Leek JT, Storey JD. Capturing heterogeneity in gene expression studies by surrogate
 variable analysis. PLoS Genet. 2007 Sep;3(9):1724–35.
- 44. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for
 RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.

723	45. Korotl	cevich G, Sukhov V, Budin N, Shpak B, Artyomov MN, Sergushichev A. Fast gene
724	set em	richment analysis [Internet]. bioRxiv. bioRxiv; 2016. Available from:
725	http://	biorxiv.org/lookup/doi/10.1101/060012
726	46. Lymai	n S, Lee YY, McLawhorn AS, Islam W, MacLean CH. What Are the Minimal and
727	Substa	intial Improvements in the HOOS and KOOS and JR Versions After Total Joint
728	Replac	cement? Clin Orthop Relat Res. 2018 Dec;476(12):2432–41.
729	47. Saeys	Y, Inza I, Larrañaga P. A review of feature selection techniques in bioinformatics.
730	Bioinf	formatics. 2007 Oct 1;23(19):2507–17.
731	48. Liu S,	Xu C, Zhang Y, Liu J, Yu B, Liu X, et al. Feature selection of gene expression data
732	for Ca	ncer classification using double RBF-kernels. BMC Bioinformatics. 2018 Oct
733	29;19(1):396.
734	49. Uzma	Al-Obeidat F, Tubaishat A, Shah B, Halim Z. Gene encoder: a feature selection
735	techni	que through unsupervised deep learning-based clustering for large gene expression
736	data. N	Jeural Comput Appl. 2022 Jun;34(11):8309–31.
737	50. Dhal H	P, Azad C. A comprehensive survey on feature selection in the various fields of
738	machi	ne learning. Appl Intell. 2022 Mar;52(4):4543-81.
738 739	machi 51. Daphr	ne learning. Appl Intell. 2022 Mar;52(4):4543–81. ne Koller MS. Toward Optimal Feature Selection. In: Saitta L, editor. ICML'96:
738 739 740	machi 51. Daphr Procee	ne learning. Appl Intell. 2022 Mar;52(4):4543–81. ne Koller MS. Toward Optimal Feature Selection. In: Saitta L, editor. ICML'96: exdings of the Thirteenth International Conference on International Conference on
738739740741	machi 51. Daphr Procee Machi	ne learning. Appl Intell. 2022 Mar;52(4):4543–81. ne Koller MS. Toward Optimal Feature Selection. In: Saitta L, editor. ICML'96: edings of the Thirteenth International Conference on International Conference on ne Learning. 340 Pine Street, Sixth Floor San Francisco CA United States: Morgan
 738 739 740 741 742 	machi 51. Daphr Procee Machi Kaufn	ne learning. Appl Intell. 2022 Mar;52(4):4543–81. ne Koller MS. Toward Optimal Feature Selection. In: Saitta L, editor. ICML'96: edings of the Thirteenth International Conference on International Conference on ne Learning. 340 Pine Street, Sixth Floor San Francisco CA United States: Morgan nann Publishers Inc.; 1996. p. 284–92.

744	techniques	[Internet].	[cited 2023 Jul	6]. Available from:
-----	------------	-------------	-----------------	---------------------

- 745 https://ieeexplore.ieee.org/abstract/document/5558966
- 53. Solorio-Fernández S, Carrasco-Ochoa JA, Martínez-Trinidad JF. A review of unsupervised
- feature selection methods. Artif Intell Rev. 2020 Feb;53(2):907–48.
- ⁷⁴⁸ 54. Ang JC, Mirzal A, Haron H, Hamed HNA. Supervised, Unsupervised, and Semi-Supervised
- Feature Selection: A Review on Gene Selection. IEEE/ACM Trans Comput Biol Bioinform.
- 750 2016 Sep-Oct;13(5):971–89.
- 55. El Aboudi N, Benhlima L. Review on wrapper feature selection approaches. In: 2016
- ⁷⁵² International Conference on Engineering & MIS (ICEMIS) [Internet]. IEEE; 2016.
- Available from: http://ieeexplore.ieee.org/document/7745366/
- 56. Gönen M AE. Multiple Kernel Learning Algorithms. J Mach Learn Res.
- 755 2011;12(64):2211–2268.
- 57. van der Maaten L, Hinton G. Visualizing Data using t-SNE. J Mach Learn Res.
 2008;9(86):2579–605.
- 58. Wang B, Zhu J, Pierson E, Ramazzotti D, Batzoglou S. Visualization and analysis of single-
- cell RNA-seq data by kernel-based similarity learning. Nat Methods. 2017 Apr;14(4):414–6.
- 59. Hinton GE, Roweis S. Stochastic Neighbor Embedding. Adv Neural Inf Process Syst
- [Internet]. 2002 [cited 2023 Jul 6];15. Available from:
- https://proceedings.neurips.cc/paper_files/paper/2002/file/6150ccc6069bea6b5716254057a1
- 763 94ef-Paper.pdf

764	60.	Raudvere U, Kolberg L, Kuzmin I, Arak T, Adler P, Peterson H, et al. g:Profiler: a web
765		server for functional enrichment analysis and conversions of gene lists (2019 update).
766		Nucleic Acids Res. 2019 Jul 2;47(W1):W191-8.
767	61.	Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and
768		interpretation of large-scale molecular data sets. Nucleic Acids Res. 2012 Jan;40(Database
769		issue):D109–14.
770	62.	Fabregat A, Jupe S, Matthews L, Sidiropoulos K, Gillespie M, Garapati P, et al. The
771		Reactome Pathway Knowledgebase. Nucleic Acids Res. 2018 Jan 4;46(D1):D649-55.
772	63.	Kelder T, van Iersel MP, Hanspers K, Kutmon M, Conklin BR, Evelo CT, et al.
773		WikiPathways: building research communities on biological pathways. Nucleic Acids Res.
774		2012 Jan;40(Database issue):D1301-7.
775	64.	Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology:
776		tool for the unification of biology. The Gene Ontology Consortium. Nat Genet. 2000
777		May;25(1):25–9.
778	65.	Reimand J, Kull M, Peterson H, Hansen J, Vilo J. g:Profilera web-based toolset for
779		functional profiling of gene lists from large-scale experiments. Nucleic Acids Res. 2007
780		Jul;35(Web Server issue):W193–200.
781	66.	Ramilowski JA, Goldberg T, Harshbarger J, Kloppmann E, Lizio M, Satagopam VP, et al. A
782		draft network of ligand-receptor-mediated multicellular signalling in human. Nat Commun.
783		2015 Jul 22;6:7866.
784	67.	Binder JX, Pletscher-Frankild S, Tsafou K, Stolte C, O'Donoghue SI, Schneider R, et al.

785 COMPARTMENTS: unification and visualization of protein subcellular localization	ation
---	-------

786 evidence. Database . 2014 Feb 25;2014:bau012.

- 68. Szklarczyk D, Gable AL, Lyon D, Junge A, Wyder S, Huerta-Cepas J, et al. STRING v11:
- 788 protein-protein association networks with increased coverage, supporting functional
- discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019 Jan

790 8;47(D1):D607–13.

701	69	Vates B	Braschi B	Grav KA	Seal RI	Tweedie S	Bruford $E\Delta$	Genenames org: the
/91	09.	I ales D,	Diasciii D,	Ulay KA.	, Seal RL,	I weedle S,	DIUIDIU LA.	Ochemanies.org. me

- HGNC and VGNC resources in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D619–25.
- 793 70. Braschi B, Denny P, Gray K, Jones T, Seal R, Tweedie S, et al. Genenames.org: the HGNC
- and VGNC resources in 2019. Nucleic Acids Res. 2019 Jan 8;47(D1):D786–92.
- 795 71. Carbon S, Ireland A, Mungall CJ, Shu S, Marshall B, Lewis S, et al. AmiGO: online access
 796 to ontology and annotation data. Bioinformatics. 2009 Jan 15;25(2):288–9.
- 797 72. Hao Y, Hao S, Andersen-Nissen E, Mauck WM 3rd, Zheng S, Butler A, et al. Integrated
- analysis of multimodal single-cell data. Cell. 2021 Jun 24;184(13):3573–87.e29.
- 799 73. Zeisel A, Hochgerner H, Lönnerberg P, Johnsson A, Memic F, van der Zwan J, et al.
- 800 Molecular Architecture of the Mouse Nervous System. Cell. 2018 Aug 9;174(4):999–

801 1014.e22.

802

803 Acknowledgments:

804	We thank the participants who provided synovial tissue and blood samples for this study. We
805	thank Alison North, Ph.D. and Christina Pyrgaki, Ph.D. from the Rockefeller University's
806	Bio-Imaging Resource Center, RRID:SCR_017791, for help with imaging and image analysis.
807	This project was funded by the Arthritis Foundation, the Block Family Foundation as well as
808	NIH R01 AR078268 (DEO), UC2AR081025 (DEO, SG), UL1 TR001866 (DEO),
809	R01AR077019 (REM), R01AR064251 (AM), R01AR060364 (AM), P30AR079206 (AM) and
810	the Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus
811	Erythematosus (AMP RA/SLE) Network. The AMP Program is a public-private partnership that
812	includes AbbVie Inc., the Arthritis Foundation, Bristol-Myers Squibb Company, the Foundation
813	for the National Institutes of Health, GlaxoSmithKline, Janssen Research and Development,
814	LLC, the Lupus Foundation of America, the Lupus Research Alliance, Merck Sharp & Dohme
815	Corp., the National Institute of Allergy and Infectious Diseases, the National Institute of Arthritis
816	and Musculoskeletal and Skin Diseases, Pfizer Inc., the Rheumatology Research Foundation,
817	Sanofi, and Takeda Pharmaceuticals International, Inc. Funding for AMP RA/SLE work was
818	provided through grants from the National Institutes of Health (UH2-AR067676, UH2-
819	AR067677, UH2-AR067679, UH2-AR067681, UH2-AR067685, UH2-AR067688, UH2-
820	AR067689, UH2-AR067690, UH2-AR067691, UH2-AR067694, and UM2-AR067678). The
821	work of ZB and FW was supported by NSF 1750326. The PEAC study was supported by
822	funding from the UK Medical Research Council (MRC) [grant number G0800648] and core
823	work was supported by grants from Versus Arthritis [Experimental Arthritis Treatment Centre,
824	grant number 20022].
825	Funding:

826 Arthritis Foundation

- 827 Block Family Foundation
- National Institutes of Health grant R01 AR078268 (DEO)
- National Institutes of Health grant UC2AR081025 (DEO, SG)
- National Institutes of Health grant UL1 TR001866 (DEO)
- National Institutes of Health grant R01AR077019 (REM)
- National Institutes of Health grant R01AR064251 (AM)
- National Institutes of Health grant R01AR060364 (AM)
- National Institutes of Health grant P30AR079206 (AM)
- Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus
 Erythematosus (AMP RA/SLE) Network
- 837 National Institutes of Health grant UH2-AR067676 (AMP RA/SLE work)
- National Institutes of Health grant UH2-AR067677 (AMP RA/SLE work)
- 839 National Institutes of Health grant UH2-AR067679 (AMP RA/SLE work)
- 840 National Institutes of Health grant UH2-AR067681 (AMP RA/SLE work)
- 841 National Institutes of Health grant UH2-AR067685 (AMP RA/SLE work)
- National Institutes of Health grant UH2-AR067688 (AMP RA/SLE work)
- National Institutes of Health grant UH2-AR067689 (AMP RA/SLE work)
- 844 National Institutes of Health grant UH2-AR067690 (AMP RA/SLE work)
- National Institutes of Health grant UH2-AR067691 (AMP RA/SLE work)
- National Institutes of Health grant UH2-AR067694 (AMP RA/SLE work)

- National Institutes of Health grant UM2-AR067678 (AMP RA/SLE work)
- National Science Foundation grant 1750326 (ZB, FW)
- UK Medical Research Council (MRC) grant G0800648 (PEAC study)
- 850 Versus Arthritis [Experimental Arthritis Treatment Centre, grant 20022] (PEAC study core
- 851 work)

Accelerating Medicines Partnership Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE) Network includes:

- ⁸⁵⁴ Jennifer Albrecht⁸, Jennifer H. Anolik⁸, William Apruzzese⁹, Brendan F. Boyce⁸, David L.
- 855 Boyle¹⁰, Michael B. Brenner⁹, S. Louis Bridges Jr.³, Christopher D. Buckley¹¹, Jane H.
- 856 Buckner¹², Vivian P. Bykerk^{1,3}, James Dolan⁹, Laura T. Donlin^{1,3}, Thomas M. Eisenhaure¹³,
- Andrew Filer¹¹, Gary S. Firestein¹⁰, Chamith Y. Fonseka^{9,13}, Ellen M. Gravallese¹⁴, Peter K.
- ⁸⁵⁸ Gregersen¹⁵, Joel M. Guthridge¹⁶, Maria Gutierrez-Arcelus^{9,13}, Nir Hacohen¹³, V. Michael
- Holers⁷, Laura B. Hughes¹⁷, Lionel B. Ivashkiv^{1,3,18}, Eddie A. James¹², Judith A. James¹⁶, A.
- Helena Jonsson⁹, Stephen Kelly¹⁹, James A. Lederer⁹, Yvonne C. Lee²⁰, David J. Lieb¹³, Arthur
- M. Mandelin II²⁰, Mandy J. McGeachy²¹, Michael A. McNamara^{1,3}, Joseph R. Mears^{9,13}, Nida
- Meednu⁸, Larry Moreland²¹, Harris Perlman²⁰, Javier Rangel-Moreno⁸, Deepak A. Rao⁹, Soumya
- Raychaudhuri^{9,13,23}, Christopher Ritchlin⁸, William H. Robinson²⁴, Mina Rohani-Pichavant²⁴,
- Karen Salomon-Escoto¹⁴, Jennifer Seifert⁷, Kamil Slowikowski^{9,13}, Darren Tabechian⁸, Jason D.
- ⁸⁶⁵ Turner¹¹, Paul J. Utz²⁴, Gerald F. M. Watts⁹, Kevin Wei⁹

- ⁸University of Rochester Medical Center, Rochester, NY, USA. ⁹Brigham and Women's
- ⁸⁶⁸ Hospital and Harvard Medical School, Boston, MA, USA. ¹⁰University of California, San Diego,

. . . .

-

869	La Jolla, CA, USA. "University Hospitals Birmingham NHS Foundation Trust and University of
870	Birmingham, Birmingham, UK. ¹² Benaroya Research Institute at Virginia Mason, Seattle, WA,
871	USA. ¹³ Broad Institute of MIT and Harvard, Cambridge, MA, USA. ¹⁴ University of
872	Massachusetts Medical School, Worcester, MA, USA. ¹⁵ Feinstein Institute for Medical
873	Research, Northwell Health, Manhasset, New York, NY, USA. ¹⁶ Oklahoma Medical Research
874	Foundation, Oklahoma City, OK, USA. ¹⁷ University of Alabama at Birmingham, Birmingham,
875	AL, USA. ¹⁸ Weill Cornell Graduate School of Medical Sciences, New York, NY, USA. ¹⁹ Barts
876	Health NHS Trust, London, UK. ²⁰ Northwestern University Feinberg School of Medicine,
877	Chicago, IL, USA. ²¹ University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
878	²² Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University,
879	Tokyo, Japan. ²³ Arthritis Research UK Centre for Genetics and Genomics, Centre for
880	Musculoskeletal Research, The University of Manchester, Manchester, UK. ²⁴ Stanford
881	University School of Medicine, Palo Alto, CA, USA.

882 Author contributions:

TTO

11----

- 883 Designing research studies: ZB, NB, MA, AM, REM, SG, FW, DEO
- 884 Designing and implementing algorithms and frameworks: ZB
- Acquiring data: MA, CH, EAM, NEB, SP, ES, ED, MHS, MJL, SS, CP, AM, REM, SG, FW,
- 886 DEO
- 887 Conducting experiments: ZB, MA, EAM, NEB, SP, AM, REM, FW, DEO
- Analyzing data: ZB, NB, MA, CH, EAM, NEB, SP, ES, ED, MHS, MOF, CSJ, HZ, MJL, SS,
- 889 CP, AM, REM, FZ, SG, FW, DEO
- 890 Writing the manuscript: ZB, NB, MA, CH, EAM, NEB, SP, ES, ED, MHS, MOF, CSJ, HZ, MJL,
- 891 SS, CP, AM, REM, FZ, SG, FW, DEO

- 892 **Competing interests:** Authors declare that they have no competing interests.
- 893 **Data and materials availability:** All data sources are available in the main text or the
- supplementary materials. For codes and any questions, please contact Zilong Bai at
- s95 zib4001@med.cornell.edu.

896 Figures









Fig. 2. Identification of a synovial gene expression signature that correlates with synovial 905 histologic cell density using GbGMI or PCA. (A) Expression heatmap of the top 5,000 906 most variably expressed genes in 38 patients. Gene expression levels (rows) are 907 represented as z-scores for all patients. Patients (columns) are sorted by their mean nuclei 908 densities. (**B**) Similarity matrix of synovial histologic cell densities. (**C**) Laplacian scores 909 of the top 5,000 most variably expressed genes measuring how their expression levels 910 911 varied compared to synovial histologic cell density similarity structure, each dot represents a gene, sorted by Laplacian score in ascending order. (D) -log(P value) of the 912 correlation of the top-k-ranked groups of genes with nuclei density similarity structure, 913 each dot represents a group of genes. (E) Synovial histologic cell density according to 914 PC1 score of the top 5,000 most variably expressed genes in 38 patients. (F) Synovial 915 histologic cell density according to the summary score of the 5,000 genes over the 38 916 patients. (G) Synovial histologic cell density according to the summary score of the 2,713 917

918 GbGMI-identified genes over the 38 patients. Statistics presented in **E**, **F**, and **G** indicate





Fig. 3. GbGMI-identification of pain-associated synovial gene expression in patients with 921 922 established and early RA. (A) Expression heatmap of 2,227 genes with increased expression in low inflammatory synovium. Patients (columns) were grouped by 923 inflammatory levels: high (n=12) versus low (n=22, low and mixed inflammatory)924 subtypes identified by (9). (B) Similarity structure of HOOS/KOOS pain scores over 925 patients. (C) Laplacian scores of the input 2,227 genes measure how their expression 926 levels over patients relate to the pain-score-based similarity structure, each dot represents 927 a gene, sorted by Laplacian score in ascending order. (**D**) Significance of the correlation 928 between the top k ranked genes and HOOS/KOOS pain scores, each dot represents a 929 930 group of genes. Established RA HOOS/KOOS pain score according to the summary score of the 815 GbGMI-identified genes in low inflammatory samples (E) or all 931 samples, irrespective of inflammatory status (F). Early RA VAS pain scores, according to 932

gene expression summary score of 738 GbGMI-identified pain-associated genes in
patients with low inflammatory (fibroid or unassigned) synovial pathotype (G) or all
patients, irrespective of synovial pathotype (H). Z-score is calculated from gene
expression values over patients. Statistics presented in E, F, G, and H indicate Kendall
correlation coefficient and P-value.





948	(n=4,354) of RA synovial cells in 18 unique cell populations (of B cells: SC-B1-4,
949	Fibroblasts: SC-F1-4, Monocytes: SC-M1-4, T cells: SC-T1-6), which were identified
950	from the 5,265 scRNA-seq profiles by an integrated analysis based on CCA from the
951	Accelerating Medicine Partnership (18). Z score is calculated on the basis of
952	log ₂ (CPM+1) transformed UMIs counts over the RA synovial cells. (E) Volcano plots of
953	794 pain genes in scRNA-seq profiles (Immport Accession #SDY998) (11) with non-zero
954	variance in expression values across the subset (n=1,532) of RA synovial fibroblasts in
955	three sublining subsets, CD34+ (SC-F1), HLA-DRAhi (SC-F2), and DKK3+ (SC-F3)
956	and one lining subset (SC-F4). Each volcano plot shows the differential expression
957	analysis (using Seurat function FindMarkers) of the genes in each RA synovial fibroblast
958	subtype compared to the other three, where x-axis shows log_2 (Fold Change) and y-axis -
959	log(adjusted p-value). The significantly increased, significantly decreased, and non-
960	significantly differentially expressed genes are indicated by different colors. The
961	horizontal and vertical red lines respectively indicate the threshold of significance [-
962	log(adjusted p-value = 0.05)] and the separation threshold between increased and
963	decreased gene expression log_2 (Fold Change) = 0.



Fig. 5. Filtering on synovial fibroblast genes predicted to influence dorsal root ganglion 965 sensory nerves. (A) Number of predicted synovial fibroblast ligands with paired DRG 966 receptors according to fibroblast subset. (B) Predicted ligand-receptor pairs between 967 synovial lining fibroblasts (SC-F4) and DRG tissue. The outermost circle indicates the 968 source of expression, synovial lining fibroblast SC-F4 or DRG tissue. The dots represent 969 whether the gene is ligand-coding or receptor-coding. The inner layer contains gene 970 names. The color of the lines connecting the gene names indicate the direction of the 971 interaction. (C) Number of predicted interactions between synovial fibroblast subsets and 972 various DRG subsets. (D) Expression heatmap of 21 pain-associated ligand/receptor 973 encoding marker genes of synovial lining fibroblast cells with non-zero variance in 974 expression values across a subset (n=4,354) of RA synovial cells in 18 unique cell 975

976	populations (of B cells: SC-B1-4, Fibroblasts: SC-F1-4, Monocytes: SC-M1-4, T cells:
977	SC-T1-6), which were identified from the 5,265 scRNA-seq profiles by an integrated
978	analysis based on CCA from the Accelerating Medicine Partnership (18). Z-score is
979	calculated on the basis of log ₂ (CPM+1) transformed UMIs counts over the RA synovial
980	cells. The genes are ranked top down by their log fold change in DEA of lining fibroblast
981	vs other fibroblasts.



982



Survival of CGRP+ DRG neurons cultured with media alone, Ngf, or Net4. Survival was
 measured by the number of Map2b+B3tub+ cells >10μm. Each dot represents the sum of
 five 10x magnification views from one experiment. Data from 4 experiments are

987	presented. ns indicates not significant in Kruskal-Wallis test. (B) Sum of sprouting
988	neurons divided by the total number of neurons cultured with media alone, Ngf, or Net4.
989	Neurons with at least three axon branches greater than two times the size of the soma
990	were classified as sprouting. Each dot represents the sum of five 10x magnification views
991	from one experiment. Data from 4 experiments are presented. ns indicates not significant
992	in Kruskal-Wallis test. (C) Representative images of Sholl analysis of branching of DRG
993	neurons cultured with media alone (no treatment), Ngf, or Net4. (D) Branching, as
994	measured by the number of shell intersections of neurites, in DRG neurons cultured with
995	media alone (no treatment), Ngf, or Net4. Each dot represents the median with
996	confidence interval of 40 neurons imaged from four experiments (10 neurons per
997	experiment). **** indicates p<0.0001 in two way ANOVA group*radius interaction with
998	post-hoc Dunnett's multiple comparisons of each treatment group to the no treatment
999	group.
1000	
1001	
1002	Supplementary Materials

1003 Materials and Methods

1004 Identify differentially expressed genes via ANOVA test on pain-level-based groupings

We investigated the association between gene expression and the grouping structure of patientreported pain in an attempt to identify individual genes that are significantly associated with pain. The 22 patients from HSS with relatively low inflammation were binned into low, medium, and high pain groups. We conducted the one-way ANOVA test between gene expression and painlevel-based groupings of data. To fully utilize the patient-reported pain data, we determine the

thresholds for splitting these 22 patients by different binning strategies applied to the 165 total 1010 patients from the HSS dataset with HOOS/KOOS pain scores on record. We investigated three 1011 1012 binning strategies: (i) quartile-based: high pain was associated with pain score below the first (lower) quartile, medium pain is defined between the first (lower) and third (upper) quartiles, and 1013 1014 low pain with the pain score above the third (upper) quartile. This resulted in 6 patients with high 1015 pain, 15 patients with medium pain, and 1 patient with low pain. (ii) 33-percentile-based: the pain scores are grouped into thirds by percentiles, i.e., 0-33, 34-66, 67-100. This resulted in 9 patients 1016 1017 with high pain, 12 patients with medium pain, and 1 patient with low pain. (iii) mean/stdev-based: 1018 the binning thresholds of pain scores are defined by the mean and standard deviation computed 1019 using the pain scores of all 165 patients. Pain scores below the mean - standard deviation 1020 encompassed patients with high pain, between mean - standard deviation and mean + standard 1021 deviation are the patients with medium pain, and above the mean + standard deviation are the patients with low pain. This resulted in 5 patients with high pain, 17 patients with medium pain, 1022 1023 and 0 patients with low pain. We performed one-way ANOVA tests using the aov() package in the R stats library. We applied FDR for multiple testing corrections using the p.adjust() function with 1024 1025 default settings to all tests for each ANOVA. No gene demonstrated statistical significance in any 1026 of these ANOVA tests after FDR-adjustment (i.e., no gene showed FDR-adjusted p-values < 0.05). Filtered by raw p-value < 0.05, we identified one gene (symbol: FAM178B) associated with pain 1027 1028 in the quartile-based grouping, 11 pain-associated genes using the 33-percentile-based grouping 1029 (Table S4), and zero pain-associated genes from the mean/stdev-based grouping of patients. We 1030 performed Pathway Enrichment Analysis on the differentially expressed genes (i.e., FDR-adjusted 1031 p-value <0.05) using g:Profiler (<u>https://biit.cs.ut.ee/gprofiler/</u>) with the default background setting 1032 for all ANOVA results with data sources for gene ontology and biological pathways specified. In

our percentile-based pain bins, we identified 4 significantly enriched (i.e. adjusted p-values <0.05)
 pathways: methanethiol oxidase activity, ferritin receptor activity, Sulfur metabolism, and TGF beta receptor signaling in skeletal dysplasias. The PEA results for the other ANOVA tests yielded
 no significantly enriched pathways (one differentially expressed gene in quartile-based grouping
 and zero significant genes in mean/stdev-based pain groupings).

1038 Ablation study of GbGMI using alternative approaches for gene prioritization

1039 To demonstrate the impact of using graph structure over patients for gene prioritization, we 1040 examined different alternatives to our Laplacian-Score-based approach for gene prioritization in 1041 our GbGMI framework to identify pain-associated genes. In particular, we sorted the genes based 1042 on the correlation tests - i.e., Pearsons, Kendall's, and Spearman's, between individual gene's expression and pain score, and the one-way ANOVA test between gene expression and the pain-1043 level-based groupings of data - i.e., the quartile-based, 33-percentile-based, mean/stdev-based 1044 1045 patient groupings as described in the previous section. The rows (corresponding with genes) in the 1046 gene expression matrix are reordered according to one of the alternative gene prioritization 1047 approaches. For fair comparison with our main results, the top 815 genes in each of these 1048 alternative gene prioritization lists are selected as the pain-associated gene module. The multi-gene 1049 expression of each alternative pain-associated gene module is embedded into univariate summary scores for the patients via t-SNE as in our GbGMI. We measure the association between the 1050 1051 different summary scores and the pain score by different correlation tests (Table S5). Note that 1052 none of these alternative gene prioritization approaches enabled GbGMI to identify statistically 1053 significant correlation between its top 815 pain-associated gene module summary score and the 1054 pain score (i.e., their p-values $\gg 0.05$). On the contrary, our GbGMI using Laplacian-Score for

1055 gene prioritization achieved $P = 0.0013 \ll 0.05$ in Kendall correlation test between its top-815 pain 1056 associated gene module summary score and the pain score.

1057 Sensitivity analysis of GbGMI on the HSS low-inflammatory patients

1058 We conducted sensitivity analysis to investigate how the patient composition affects the gene 1059 prioritization and pain-associated gene subset identification results on the HSS dataset. Specifically, we subsampled the n=22 low-inflammatory patients with the leave-one-out strategy, 1060 resulting in 22 different subsampled datasets. On each subsampled dataset, we applied our GbGMI 1061 framework to build its pain-score similarity matrix, compute the Laplacian scores for the m=2,227 1062 1063 low-inflammatory genes for prioritization, and determine the cut-off using t-SNE embeddings and 1064 correlation test between summary score and pain score to identify the pain-associated gene subset. 1065 The resultant 23 (22 for subsampled and 1 for overall) pain-associated gene prioritization gene 1066 lists and pain-associated gene subsets are compared to demonstrate how sensitive our GbGMI is 1067 with respect to changes in patient set. Each pair of gene prioritization gene lists are compared via Spearman's correlation test, with the minimum correlation coefficient $\rho_{min} = 0.7472$ and all p-1068 values « 0.05. (Fig. S6A for pairwise correlation coefficient heatmap.) Each pair of pain-1069 associated gene subsets are compared using the Fisher's exact test, with the m=2,227 low-1070 1071 inflammatory genes as the background genes. Note that p-value $\ll 0.05$ between the pain-1072 associated gene identification results of each leave-one-out patient subset and the overall relatively 1073 low-inflammatory patient set. Only 9 pairs of patient subsets with single patient excluded did not 1074 show significant overlap (p-value >0.05), e.g., exclude-RA57.SYN vs exclude-RA147.SYN. (Fig. 1075 S6B for pairwise Fisher's exact test p-value heatmap.)

1076

1077 Methodological Validation of GbGMI on the early RA dataset.

In this section, we validate the consistency of low-inflammatory pain-associated genes identified 1078 1079 across the established RA (i.e., HSS (9) and the early RA datasets (i.e., PEAC (10)). For fair 1080 comparison, the gene list from RNA-seq on PEAC is intersected with the m=2,227 lowinflammatory genes that we identified from the HSS dataset, resulting in a 2,018-gene list for low-1081 1082 inflammatory genes on PEAC. Among the 2,018 PEAC low-inflammatory genes, 738 were 1083 identified to be pain-associated by GbGMI from the HSS dataset. To directly identify pain-1084 associated genes with GbGMI from the 2,018 PEAC low-inflammatory genes, we grouped the samples labeled as fibroid or ungraded early RA subset and formed a low-inflammatory subset of 1085 n=22 patients. GbGMI was applied to this 2,018 \times 22 PEAC low-inflammatory gene expression 1086 matrix and identified a 658-gene module significantly associated with pain measured by VAS 1087 1088 score. The 738 HSS and the 658 PEAC pain associated genes demonstrated significant overlap (p-1089 value = 0.0016 and 95% CI [1.1215, 1.6598]) in Fisher's exact test with the 2,018 PEAC low-1090 inflammatory genes as background).

1091 Ligand-receptor analysis using mouse nervous system scRNA-seq

1092 We also performed ligand-receptor interaction analysis between the pain-associated genes 1093 expressed by the four synovial fibroblast subtypes (CD34+ sublining fibroblasts [SC-F1], HLA-1094 DRAhi sublining fibroblasts [SC-F2], DKK3+ sublining fibroblasts [SC-F3], and CD55+ lining 1095 fibroblasts [SC-F4]) (18) and a mouse nervous system scRNAseq dataset from an adolescent 1096 mouse nervous system dataset (73). We predicted considerable connections between lining 1097 fibroblasts (SC-F4) and peripheral sensory neurofilament, peptidergic and non-peptidergic 1098 neurons, as well as sympathetic cholinergic and noradrenergic neurons (Fig. S7). As we will detail 1099 in the following, we considered three different scenarios to identify differentially expressed genes 1100 in a specific neuronal subpopulation from the mouse nervous system scRNA-seq data: each

neuronal cell type vs all the other cell types (including non-neurons), each neuronal cell type vs
the other neurons, and comparison among three different specific neuron subtypes (i.e., peripheral
sensory neurofilament neurons, peripheral sensory peptidergic neurons, and peripheral sensory
non-peptidergic neurons) (Fig. S7).

1105

1106 Data: We used the scRNA-seq data from a mouse nervous system dataset (73) to generate the 1107 transcriptome profile of individual cell-types in the adolescent mouse nervous system. Our analysis used the expression values and metadata for each subpopulation of component cells provided by 1108 1109 the original publication. The raw sequence data is deposited in the sequence read archive under 1110 accession SRP135960 in the National Center for Biotechnology Information (NCBI) library. The 1111 cell subpopulations identified in this mouse nervous system scRNA-seq dataset comprises 1112 subpopulations of cells (mainly neurons), from both central (CNS) and peripheral nervous systems 1113 (PNS) (73).

1114

Method: We predicted interactomes for ordered pairs of tissues or cell types that we investigate 1115 1116 based on the overall interactome containing more than 3,000 interactions (denoted I^{o}) built by 1117 (19). We identified ligand-to-receptor unidirectional signaling from one tissue or cell type to 1118 another. To identify the interactome for a specific ordered pair of tissue or cell types, the ligandencoding genes from I^{o} were intersected with the genes that satisfy the ligand-side inclusion 1119 1120 criteria in all samples/cells in a specific tissue or cell type wherein we investigate the upstream component of the signaling, and similarly the receptor-encoding genes of I^{o} were intersected with 1121 the genes satisfying receptor-side inclusion criteria in another specific tissue or cell type wherein 1122 1123 we investigate the downstream component of the signaling.

We generated the interactomes between each of the 4 synovial fibroblast subtypes (18) and each 1124 selected specific neuronal subpopulation of the mouse nervous system (73). On the mouse nervous 1125 system scRNA-seq data, we considered three different scenarios to identify differentially 1126 expressed genes in a specific neuronal subpopulation: (a) each neuronal cell type vs all the other 1127 cell types (including non-neurons), (b) each neuronal cell type vs the other neurons, and (c) 1128 1129 comparison among three different specific neuron subtypes (i.e., peripheral sensory neurofilament neurons, peripheral sensory peptidergic neurons, and peripheral sensory non-peptidergic neurons). 1130 1131 In each scenario, the differentially expressed genes (i.e., adjusted p-value <0.05) with higher 1132 expression values in a specific neuronal cell type are identified by the FindMarkers function from the R package Seurat (72) to be the marker genes of a specific neuronal subpopulation. We present 1133 the two unidirectional interactomes of each scenario in Fig. S7, where we also summarize the 1134 quantity of ligand-receptor interactions associated with each specific fibroblast or neuronal cell 1135 type, as well as the total number of interactions, in each tissue-wise direction. 1136

1137 Supplementary Figures



1139 Fig. S1. Overview of Study. Graph-based Machine Learning with Clinical Data and Gene

1140 Expression Data Identified Synovial Fibroblast Genes Associated with Pain which Affect

1141 Sensory Nerve Growth in Rheumatoid Arthritis.



1142

Fig. S2. A diagram illustrating the framework of GbGMI for identifying a synovial gene 1143 expression signature that associates with pain. (A) Construction of similarity matrix over 1144 1145 patients based on a univariate patient-level attribute (e.g., HOOS/KOOS pain score). (B) Computing Laplacian score for each gene by measuring the concordance between its expression 1146 values and the similarity matrix S of pain scores from the same set of patients. (C) Synovial gene 1147 expression matrix with genes sorted by their Laplacian scores in ascending order to form the 1148 1149 gene prioritization list \mathcal{L}_s , according to which the rows of the gene expression matrix M are 1150 reordered. (**D**) Generating the gene expression summary score vector s_k for each candidate group 1151 of top k genes from \mathcal{L}_s by performing the 1-dim t-SNE embedding on their $k \times n$ gene expression submatrix $M_{1:k*}$. (E) Performing correlation tests between the gene expression 1152 summary score s_k and the input univariate pain score a over the same patients. The k^* where the 1153 significance of correlation coefficients peaks is used to select the group of top k^* genes from the 1154 prioritization list \mathcal{L}_s as the synovial gene expression signature that is significantly associated 1155 with pain. 1156





Fig. S3. GbGMI-identified pain-associated synovial gene expression compared against VAS
pain scores in patients with established RA at different levels of synovial inflammation. (A),
(B), and (C): Condition-caused VAS pain score according to the summary score of the 815

1161 GbGMI-identified genes in patients with low synovial inflammation (n=22), high synovial 1162 inflammation (n=12), and overall patients with different levels of synovial inflammation (n=34) 1163 respectively.



Fig. S4. GbGMI-identified pain-associated gene expression increases with increasing pain 1165 severity. (A) Volcano plot,-log10(nominal p value) and LogFC(Pain score), of differential 1166 1167 expression analysis with LIMMA (14) for all genes (grey dots) and 815 GbGMI-identified painassociated genes (red dots) in the bulk RNA-seq data (9). (B) Cumulative distribution versus t-1168 statistic comparing the 815-gene set and the set of all genes in synovial tissue gene expression 1169 1170 data (9). (C) GSEA querying the 815 pain-associated genes on the genes from the expression data sorted by differential expression analysis (see Materials and Methods). Analysis of GbGMI-1171 1172 identified genes in (A), (B), and (C) consistently indicated that the pain-associated 815 genes as 1173 a group decreased expression as the HOOS/KOOS pain score increases, hence indicating their positive correlation with pain severity. 1174



1175

1176 Fig. S5. Representative staining of CGRP+ DRG neuron *in vitro*.



1178 Fig. S6. Sensitivity analysis of GbGMI on the HSS low-inflammatory patients. (A) Heatmap

- 1179 of Spearman correlation coefficient between each pair of Laplacian-Score-based gene
- 1180 prioritization lists generated using different patient subsets. (B) Heatmap of Fisher's exact test p-
- values between the pain-associated gene module identification results of different patient subsets.
- 1182 In both (A) and (B), the first 22 rows/columns indicate the leave-one-out patient subsets, the last
- 1183 rows/columns indicate all the 22 patients with relatively low inflammation from the HSS cohort.





1193	receptor genes. The middle layer shows whether a gene is ligand-coding or receptor-coding in its
1194	associated interactions. The inner layer contains gene names. The two tissue-wise directions are
1195	distinguished by the colors of connections between gene names. The number of connections
1196	associated with the ligand/receptor genes in each fibroblast subtype or neuron subtype and in
1197	each unidirectional tissue-wise relation are summarized in the corresponding legends.
1198	
1199	Table S1: Pathway Analysis (Data file S1) Pathway enrichment analysis for the GbGMI
1200	identified 815-gene pain-associated genes. Modified Fisher's exact test based on the
1201	hypergeometric distribution; - log ₁₀ of P-values after multiple testing correction with g:SCS (65)
1202	are color-coded for the GO: Biological Processes (BP) terms (adjusted P-value < 0.05)
1203	
1204	Table S2: Fibroblast-DRG receptor ligand interaction analysis (Data file S2) The ligand-
1205	receptor pairs identified between the pain-associated genes expressed by four synovial fibroblast
1206	subtypes in human RA synovial tissue and expressed genes in a human DRG bulk RNA-seq
1207	dataset (20). Ligand-coding and receptor-coding gene symbols are in the "ligand_gname" and
1208	"receptor_gname" columns respectively. The RA fibroblast subtypes of the ligand-coding genes
1209	are annotated in the column "ligand_cell_type". The "receptor_tissue" is human DRG.
1210	Table S3: Fibroblast-Sensory nerve subset receptor ligand interaction analysis (Data file
1211	$\mathbf{S3}$) The ligand-receptor pairs identified between the pain-associated genes expressed by the
1212	synovial fibroblast subsets (18) and a mouse scRNA-seq DRG dataset (21). Ligand-coding and
1213	receptor-coding gene symbols are in the "ligand_gname" and "receptor_gname" columns
1214	respectively. The receptor coding genes symbols are translated from mouse gene symbols to their
1215	human gene symbol counterparts. The "receptor_cell_type" column denotes the neuronal cell

- types from the mDRG dataset of each receptor-coding gene. The column "ligand_cell_type"
- 1217 denotes the RA fibroblast subtype of each ligand-coding gene.

Gene	FDR Adjusted Pval
SELENBP1	0.024
FAM178B	0.024
MAP7D2	0.048
SLC22A17	0.048
ZNF423	0.048
PLEKHA4	0.049
KHDRBS3	0.048
LTBP3	0.049
SCARA5	0.048
AC106786.1	0.048
CTD-3049M7.1	0.048

1218 Table S4. Differentially expressed genes (FDR-adjusted p-value<0.05) identified by

1219 ANOVA test using the pain-score percentile-based patient grouping.

Alternative gene	P-value of correlation test between top 815-gene module			
prioritization approach	summary score and pain score			
	Kendall	Pearson	Spearman	
Kendall's correlation	0.6509	0.5643	0.6905	
Pearson's correlation	0.6107	0.8613	0.7053	
Spearman's correlation	0.9099	0.446	0.8083	
ANOVA test (quantile- based patient grouping)	0.7343	0.9247	0.6979	
ANOVA test (33- percentile-based patient grouping)	0.4284	0.5960	0.3686	
ANOVA test (mean/stdev-based patient grouping)	0.7343	0.7613	0.8375	

1220 Table S5. Correlation tests between the top 815-gene modules identified by GbGMI using

1221 different alternative gene prioritization approaches as alternatives to our Laplacian-Score

- approach and the pain score. The p-values of Kendall's, Pearson's, and Spearman's correlation
- tests between the top 815-gene module summary scores yielded by the different gene
- 1224 prioritization approaches and the pain score are presented.

1225